Anavex Life Sciences Corp (AVXL)

[falconer66a]

Investment Public Gives Not a Hoot About MRIs

Yes, those of us who know are excited, encouraged about the (rather certain) probability that MRI or other new diagnostic methods will allow Anavex Life Sciences Corp to favorably select for any of its up-coming clinical trials patients with elevated, positive responses to Anavex 2-73. Keep out non-responders; test only on people who will respond favorably. With that, the clinical deck is stacked in Anavex’s favor. Test the drugs on populations of people pre-determined to have the genes or other factors that positively respond to Anavex treatment.

Still, for the vast majority of biotech investors, none of that will prompt new, higher-price AVXL buying. Those folks will wait until they see actual human, clinical trial outcomes. When any of those are positive, AVXL has a certain profitable future. Until then, before clinical results are learned, it’s all conjectural. The only thing that will drive AVXL prices significantly higher (say, >$10), will be real clinical results on real, diseased people.